420 related articles for article (PubMed ID: 17996858)
1. Application of drug metabolising mutants of cytochrome P450 BM3 (CYP102A1) as biocatalysts for the generation of reactive metabolites.
Damsten MC; van Vugt-Lussenburg BM; Zeldenthuis T; de Vlieger JS; Commandeur JN; Vermeulen NP
Chem Biol Interact; 2008 Jan; 171(1):96-107. PubMed ID: 17996858
[TBL] [Abstract][Full Text] [Related]
2. The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities.
Yun CH; Kim KH; Kim DH; Jung HC; Pan JG
Trends Biotechnol; 2007 Jul; 25(7):289-98. PubMed ID: 17532492
[TBL] [Abstract][Full Text] [Related]
3. Application of CYP102A1M11H as a tool for the generation of protein adducts of reactive drug metabolites.
Boerma JS; Vermeulen NP; Commandeur JN
Chem Res Toxicol; 2011 Aug; 24(8):1263-74. PubMed ID: 21639118
[TBL] [Abstract][Full Text] [Related]
4. Role of residue 87 in the activity and regioselectivity of clozapine metabolism by drug-metabolizing CYP102A1 M11H: application for structural characterization of clozapine GSH conjugates.
Rea V; Dragovic S; Boerma JS; de Kanter FJ; Vermeulen NP; Commandeur JN
Drug Metab Dispos; 2011 Dec; 39(12):2411-20. PubMed ID: 21890734
[TBL] [Abstract][Full Text] [Related]
5. Generation of human metabolites of 7-ethoxycoumarin by bacterial cytochrome P450 BM3.
Kim DH; Kim KH; Kim DH; Liu KH; Jung HC; Pan JG; Yun CH
Drug Metab Dispos; 2008 Nov; 36(11):2166-70. PubMed ID: 18669587
[TBL] [Abstract][Full Text] [Related]
6. Identification of critical residues in novel drug metabolizing mutants of cytochrome P450 BM3 using random mutagenesis.
van Vugt-Lussenburg BM; Stjernschantz E; Lastdrager J; Oostenbrink C; Vermeulen NP; Commandeur JN
J Med Chem; 2007 Feb; 50(3):455-61. PubMed ID: 17266197
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of alkoxyresorufins as fluorescent substrates for cytochrome P450 BM3 and site-directed mutants.
Lussenburg BM; Babel LC; Vermeulen NP; Commandeur JN
Anal Biochem; 2005 Jun; 341(1):148-55. PubMed ID: 15866539
[TBL] [Abstract][Full Text] [Related]
8. Improved detection of reactive metabolites with a bromine-containing glutathione analog using mass defect and isotope pattern matching.
Leblanc A; Shiao TC; Roy R; Sleno L
Rapid Commun Mass Spectrom; 2010 May; 24(9):1241-50. PubMed ID: 20391594
[TBL] [Abstract][Full Text] [Related]
9. Role of human glutathione S-transferases in the inactivation of reactive metabolites of clozapine.
Dragovic S; Boerma JS; van Bergen L; Vermeulen NP; Commandeur JN
Chem Res Toxicol; 2010 Sep; 23(9):1467-76. PubMed ID: 20849150
[TBL] [Abstract][Full Text] [Related]
10. Generation of human chiral metabolites of simvastatin and lovastatin by bacterial CYP102A1 mutants.
Kim KH; Kang JY; Kim DH; Park SH; Park SH; Kim D; Park KD; Lee YJ; Jung HC; Pan JG; Ahn T; Yun CH
Drug Metab Dispos; 2011 Jan; 39(1):140-50. PubMed ID: 20962060
[TBL] [Abstract][Full Text] [Related]
11. Efficient screening of cytochrome P450 BM3 mutants for their metabolic activity and diversity toward a wide set of drug-like molecules in chemical space.
Reinen J; van Leeuwen JS; Li Y; Sun L; Grootenhuis PD; Decker CJ; Saunders J; Vermeulen NP; Commandeur JN
Drug Metab Dispos; 2011 Sep; 39(9):1568-76. PubMed ID: 21673132
[TBL] [Abstract][Full Text] [Related]
12. Screening and identification of GSH-trapped reactive metabolites using hybrid triple quadruple linear ion trap mass spectrometry.
Zheng J; Ma L; Xin B; Olah T; Humphreys WG; Zhu M
Chem Res Toxicol; 2007 May; 20(5):757-66. PubMed ID: 17402749
[TBL] [Abstract][Full Text] [Related]
13. Filling a hole in cytochrome P450 BM3 improves substrate binding and catalytic efficiency.
Huang WC; Westlake AC; Maréchal JD; Joyce MG; Moody PC; Roberts GC
J Mol Biol; 2007 Oct; 373(3):633-51. PubMed ID: 17868686
[TBL] [Abstract][Full Text] [Related]
14. Effect of human glutathione S-transferase hGSTP1-1 polymorphism on the detoxification of reactive metabolites of clozapine, diclofenac and acetaminophen.
Dragovic S; Venkataraman H; Begheijn S; Vermeulen NP; Commandeur JN
Toxicol Lett; 2014 Jan; 224(2):272-81. PubMed ID: 24185126
[TBL] [Abstract][Full Text] [Related]
15. Effect of human glutathione S-transferases on glutathione-dependent inactivation of cytochrome P450-dependent reactive intermediates of diclofenac.
Dragovic S; Boerma JS; Vermeulen NP; Commandeur JN
Chem Res Toxicol; 2013 Nov; 26(11):1632-41. PubMed ID: 24083800
[TBL] [Abstract][Full Text] [Related]
16. The dimeric form of flavocytochrome P450 BM3 is catalytically functional as a fatty acid hydroxylase.
Neeli R; Girvan HM; Lawrence A; Warren MJ; Leys D; Scrutton NS; Munro AW
FEBS Lett; 2005 Oct; 579(25):5582-8. PubMed ID: 16214136
[TBL] [Abstract][Full Text] [Related]
17. A highly active single-mutation variant of P450BM3 (CYP102A1).
Whitehouse CJ; Bell SG; Yang W; Yorke JA; Blanford CF; Strong AJ; Morse EJ; Bartlam M; Rao Z; Wong LL
Chembiochem; 2009 Jul; 10(10):1654-6. PubMed ID: 19492389
[TBL] [Abstract][Full Text] [Related]
18. Trimethoprim: novel reactive intermediates and bioactivation pathways by cytochrome p450s.
Damsten MC; de Vlieger JS; Niessen WM; Irth H; Vermeulen NP; Commandeur JN
Chem Res Toxicol; 2008 Nov; 21(11):2181-7. PubMed ID: 18816075
[TBL] [Abstract][Full Text] [Related]
19. Laboratory evolution of P450 BM3 for mediated electron transfer yielding an activity-improved and reductase-independent variant.
Nazor J; Dannenmann S; Adjei RO; Fordjour YB; Ghampson IT; Blanusa M; Roccatano D; Schwaneberg U
Protein Eng Des Sel; 2008 Jan; 21(1):29-35. PubMed ID: 18093991
[TBL] [Abstract][Full Text] [Related]
20. Expression, purification, and characterization of Bacillus subtilis cytochromes P450 CYP102A2 and CYP102A3: flavocytochrome homologues of P450 BM3 from Bacillus megaterium.
Gustafsson MC; Roitel O; Marshall KR; Noble MA; Chapman SK; Pessegueiro A; Fulco AJ; Cheesman MR; von Wachenfeldt C; Munro AW
Biochemistry; 2004 May; 43(18):5474-87. PubMed ID: 15122913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
